Skip to content
Guess what? Valuesider just got better: smarter and more intuitive.
Thermo Fisher Scientific Inc

TMO

Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc historical holders

total: 22

Fairfax Financial Holdings Thermo Fisher Scientific Inc transactions over time

Total transactions:
2
New positions:
1
Sold out:
1
Held since:
2017 Q1
Held for:
4 quarters
Latest activity:
2018 Q1
Prem Watsa has been an institutional investor in Thermo Fisher Scientific Inc (TMO) since 2017 Q1. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired TMO in 2017 Q1, initially purchasing 1,344 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.

When did Prem Watsa exit their TMO position?

Prem Watsa no longer holds Thermo Fisher Scientific Inc (TMO). They sold off their entire position in 2018 Q1, closing out an investment that began in 2017 Q1.

When did Prem Watsa first invest in TMO?

Prem Watsa first invested in Thermo Fisher Scientific Inc (TMO) in 2017 Q1 at the reported quarter-end price of $153.27 per share, acquiring 1,344 shares in their initial purchase.

What is Prem Watsa's average cost basis for TMO?

Based on historical transaction data, Prem Watsa's estimated cost basis for Thermo Fisher Scientific Inc (TMO) is approximately $153.27 per share. This represents their average reported price* across all buy transactions.

Estimated cost basis*

Weighted AVG buy price:
$153.27
Weighted AVG sell price:
$189.73

TMO transactions history by Fairfax Financial Holdings

2 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2018 Q1
0.00%
$189.73
-100% (-1,344)
2017 Q1
0.02%
$153.27
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.